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Summary.-The relationship between the utilization of 3H-thymidine in situ ([3H]-
TdR fractional incorporation or TFI) and tumour growth delay after treatment with
various cytotoxic agents has been examined. It is shown that (a) it is not possible
to predict tumour growth delay, or to select the most effective agent, from changes in
TFI 1 day after treatment; (b) there is a good correlation between tumour growth
delay and the time for recovery of TFI to the pretreatment level; (c) there is arelation-
ship within a tumour line between the depression of TFI 4 days after treatment and
growth delay induced by the same treatment. This relationship appears to be
independent of the mechanism by which the agent exerts its cytotoxic effect.
THE accurate measurement of tumour
response to a cytotoxic agent is necessary
before we can evaluate the efficacy of
individual agents, or combinations of
agents. In the laboratory under defined
conditions, measurements such as tumour
growth delay, in vitro clonogeInic cell
survival (Steel and Adams, 1975), or the
proportion of animals cured when treat-
ment is initiated soon after tumour-cell
inoculation, have been used to assess
quantitatively the valtue of new and
established agents. At present there is
no single method of assessment that can
be used with absolute confidence with
every drug-tumour combination (Connors
and Phillips, 1975), but tumour growth
inhibition probably serves as the most
useful parameter to evaluate drug efficacy
in the laboratory.
In the clinic, evaluation of agents
becomes far more difficult, and partial or
complete tumour regression has been
taken to indicate the usefulness of an
agent. However, the methods used to
measure regression are subject to con-
siderable error (Moertel, 1976) and com-
parison of results from various clinical
trials canI to lead to confuision over the
clinical value of an agent (Carter and
Friedman, 1974). Tumour volume regres-
sion per se must be regarded with caution,
as Steel and Adams (1975) have shown a
very small volume regression in a rodent
carcinoma after treatment with cyclo-
phosphamide, when the surviving fraction
of clonogenic cells was about 10-6.
Clinically, the measurement of tumour
growth inhibition may be more sensitive
as an indicator of drug effect, but at
present is practical for only a few tumour
sites.
Many attempts have been made to
relate changes in the in vitro incorporation
of radiolabelled precursors into tumour
DNA, to the subsequent patient response.
In order to predict the tumour sensitivity
in an individual patient, tumour biopsy
material has been incubated with various
cytotoxic agents, and the drug producing
the greatest inhibition of DNA precursor
utilization has generally been regarded as
potentially the most active against that
tumour (Wheeler, Dendy and Dawson,
1974; Wolberg, 1971). Other workers
have compared the differential response
between the neoplastic biopsy and normal
tissue, drug selection being determined byTdR INCORPORATION AND GROWTH IN TUMOUR XENOGRAFTS
this differential (Tisman, Herbert and
Edlis, 1973; Jzsak et al., 1971). Alter-
natively, serial tumour biopsies have been
taken after treatment and the radio-
labelled precursor utilization in vitro
compared with that in pretreatment
material (Murphy et al., 1975). Several of
these studies have suiggested that there is
a correlation between the depression of
DNA synthesis by agents after treatment
in vitro and a positive clinical response
(Livingston et al., 1974: Wheeler et al.,
1974: Sky-Peck, 1971).
In previous studies with two trans-
plantable murine tumours (Houghton
and Taylor, 1977a) we have shown that
the time taken in vivo for the fractional
incorporation of 3H-thymidine (TFI) into
tumour DNA to recover to its pretreat-
ment level, and the growth delay induced
by the same treatment were similar. In
this paper, we describe further studies of
the relationship between changes in TFI
and growth delay in 4 human colonic
tumour xenografts, maintained in immune
deprived mice, after treatment with
various cytotoxic agents. In particular
N-e have considered the following ques-
tions: (a) Are tumour growth delay and
TFI recovery time (i.e. the time required
for TFI to return to the pretreatment
level) always similar? (b) In different
tumour lines, does the same depression of
TFI correspond to a similar growth delay
following a particular treatment? (c) Is the
initial (24-h or 48-h) depression of TFI
related to the degree of growth delay
produced by different but equally toxic
treatments? (d) With a particular tumour
line, is there a relationship between the
depression of TFI at a given time after
treatment and growth delay, which is
independent of the mechanism by which
the agent kills cells?
MATERIALS AND MIETHODS
Immune deprivation. Four-w eek-old
male and female CBA/LAC mice (bred from
stock originally supplied by the Laboratory
Animal Centre, Carshalton, Surrey) were
thymectomized, and 3 -weeks later subjected
to lethal wAhole-body 60Co , radiation
(900 rad at 60 rad/min). Within 4 h of
irradiation the mice wNere given 5 x 106
syngeneic bone marrow cells suspended in
Medium 199, by i.v. injection. These cells
wNere obtained from the femurs and tibias
of mice of the same age, thymectomized 3
weeks previously. The animals wA,ere used
for t,umour implantation 2 wA-eeks after the
bone marrow transplants.
Tumour lines.-The 4 human colonic
tumour lines used in this study wiill be
described in greater detail in a subsequent
publication (Houghton and Taylor, in pre-
paration). Briefly they constitute the follow-
ing, listed in decreasing order of differentia-
tion:
HxHC1-a moderately wiell differentiated
adenocarcinoma of the ascending
colon, maintained only in female
mice.
HxGC3-a poorly differentiated adenocar-
cinoma of the transverse colon,
maintained in male mice.
HxVRC5 a poorly differentiated adenocar-
cinoma of the caecum, maintained
in male mice.
HxELC2-a poorly differentiated carcinoma
of the caecum, maintained in male
mice.
Tumour transplantation8s.-Tumours Awere
serially transplanted on reaching a diameter
of 2 cm, tumours from male and female mice
being re-transplanted into the same sex.
Pieces approximately 8 mm3 were cut and
placed in Medium 199 containing penicillin
(200 u/ml) and streptomycin (100 Mg/ml).
Four pieces wAere implanted into the dorsal
flanks and in this study over 900/ of tumour
pieces gave rise to tumours.
Tumour measurement. Caliper measure-
ments of the tuumours were initiated about 3
weeks after implantation. Two perpen-
dicular diameters were measured every 3
days and the tumour volume wias calculated
using the formula Vol=7T/6 d3, where d is the
mean diameter. Tumours M-ere treated at,
8 mm diameter, and growth delay was
assessed as the increase in the time required
for the treatment tumours to grow to 4 x
their treatment, volume, over the time taken
for untreated tumours to show! the same
growth. The assessment of the induced
growth inhibition at 4 x the treatment
volume allow-s a sufficient period for the
207P. J. HOUGHTON, J. A. HOUGHTON AND D. M. TAYLOR
elimination of drug-produced debris. For
calculation of growth delay induced by an
agent, the change in "relative tumour
volume" has been plotted against time after
treatment.
The relative tumour volume is the mean
cumulative percentage increment (I) in
tumour volume, measured every 3 days, and
is calculated from the formula:
I Vol y-Vol x 100 Vol x
where Vol y is tumour volume 3 days after
Vol x. The changes in relative volume of in-
dividual tumours have been pooled, in some
experiments including more than 30 tumours.
Labelled thymidine fractional incorporation
(TFI) assay.-The measurement of TFI has
been described previously (Houghton and
Taylor, 1977a). Animals were given 25 [tCi
3H-6-TdR (Radiochemical Centre, Amersham,
sp. act. 27 Ci/mmol) at various times after
administration of the cytotoxic agent, and
were killed 1 h later. Tumours were rapidly
excised and frozen (-26°C) until being
submitted to a modified Schmidt-Thann-
hauser extraction (Munro and Fleck, 1968).
In these experiments, tumours were weighed
and homogenized in KOH (0-3M) and
incubated in sealed tubes for 12 h at 37°C.
Samples were cooled (2°C), neutralized with
cold HCI (1M) and acidified to 0-2M With
perchloric acid (PCA). After centrifugation,
the supernatant was decanted, and the pellet
was resuspended in cold PCA (0 2M). After
further centrifugation, the supernatants of
individual tumours were combined to give
the non-incorporated fraction (i.e. acid-
soluble and RNA) F1, for each individual
tumour. DNA was extracted twice by
incubating each resuspended pellet in PCA
(1M) at 67°C. The combined DNA extracts
constitute the incorporated radioactivity
fraction (F2) for each individual tumour.
Fractional incorporation is calculated as:
TFIJ F2 (ct/mmn) _< 100 F1+F2 (ct/min)
Radioactivity was measured by liquid scintil-
lation spectrometry (Intertechnique Ltd,
Model SL40) as previously described (Taylor,
Tew and Jones, 1976).
In this study, the animals received a
single i.p. injection of the cytotoxic agent.
The highest dose of each agent used was
lethal in 50% of animals (LD5) except in the
case of tumour HxGC3 where the highest
dose of cyclophosphamide studied was the
LD1o.
RESULTS
TFI in untreated tumours
Initial studies showed that TFI
decreased with increasing tumour mass
in each of the 4 xenograft lines studied
(Fig. 1). In tumour lines HxELC2 and
HxHC, a plateau was reached at about
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FIG. 1.-The TFI in 4 tumour lines plotted against tumour weight. In each case TFI initially
decreased during tuimour growth.
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0 8 g, whereas in tumour lines HXVRC5
and HxGC3 TFI stabilized at about 0 4 g.
Consequently, where TFI has been
measured after chemotherapy, the result
has been expressed as a percentage of that
in untreated tumours of equal weight.
The reason for this decrease in TFI during
tumour growth is not clear, although the
results suggest a decrease in growth
fraction during the initial "macroscopic"
growth period. A decrease in [3H]TdR
labelling index has been reported during
growth ofthe Lewis lung rodent carcinoma
(Simpson-Herren, Sandford and Holm-
quist, 1974). However, the most likely
explanation for the decreased [3H]TdR
utilization during tumour growth is that
the precursor penetrates into necrotic
zones within the tumour, where it is not
incorporated into DNA. The peripheral
band of viable tissue maintains a constant
thickness during tumour growth (although
the actual thickness differs between
tumour lines), hence with increasing
tumour diameter the proportion of viable
to necrotic tissue decreases exponentially.
The rate of decrease depends upon the
thickness of the viable tissue band. The
plateau in TFI may be explained by the
radiolabelled precursor being able to
penetrate a limited distance into the
central necrosis within I h of administra-
tion. Hence with further tumour
growth the ratio of viable to necrotic
tissue which the [3H]TdR may penetrate
in a given time will remain fairly constant.
growth delay tended to be observed when
depression of TFI was greatest, the
correlation is not statistically significant
(r 0 42 at 13 degrees of freedom). It
must be concluded therefore that, neither
within nor between series of tumours, is it
possible to relate the degree of depression
of [3H]-TdR utilization 24 h after treat-
ment with growth delay.
TABLE I.-The Change in TFI 24 h after
Treatment Related to the Mean Growth
Delay for the Corresponding Treatment.
All Agents were Given at Equitoxic Dose
(LD5s). Indicates aDepression inTFI; +
Indicates an Increase.
Tuimour
line
Change in
TFI
(0 Growth
Dose control) delay
Drug (mg/kg) at 24 h (h)
HxHCI CY
FU
Me CCNU
Act D
HxGC3 CY
Fu
Me CCNU
Act D
HxVRC5 CY
Fu
Me CCNU
HxELC2 Cy
Fu
Me CCNU
Act D
200 - 21 none
200 +42 none
35 - 40 100
0 3 0 none
200 - 29 170
200 - 24 30
35 - 47 165
0 3 - 65 70
200
200
35
- 56 580
- 3 0
- 39 560
200 - 66 670
200 - 94 1140
35 - 54 170
0 3 -90 140
The relationship between early TFI changes
and growth delay
In each of the 4 tumour lines, the
depression of TFI at 24 h after drug
treatment has been compared with the
subsequent growth delay with one of the
following agents: cyclophosphamide (CY),
5-fluorouracil (FU), 1-(2-chloroethyl)-3-
trans-4-methyl cyclohexyl)-l-nitrosourea
(Me CCNU) or actinomycin D (Act D), at
equi-toxic levels (LD5). The results are
shown in Table I. Although a long
The relationship between TFI recovery time
and growth delay
Our previous study, using two trans-
plantable rodent tumours, showed that the
time taken for TFI to recover to the pre-
treatment levelwas similar to the duration
of tumour growth inhibition for treatment
with either CY or 6OCo radiation (Hough-
ton and Taylor, 1977a). The relationship
between these two parameters has now
been investigated in the 4 human tumour
xenograft lines after treatment with
various cytotoxic agents.
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DOSE OF CYCLOPHOSPHAMDE
mg!kg
FIG. 2. (a) The pattern of TFI in tumour
line HxGC3 after various dose levels of
CY: A 100; 0 150; *-200; [2 300
mg/kg. Depression is rapid. (b) The TFI
recovery time is plotted against dose of
CY (meantLs.e.).
Fig. 2a shows the changes in TFI in
tumour line HxGC3 after various doses
of CY. It is clear that, 24-48 h after
treatment, the depression in TFI is not
simply related to the dose of CY. How-
ever, when the recovery time is plotted
against the corresponding dose of CY
(Fig. 2b) there is a clear correlation
between them.
Fig. 3 shows the changes in TFI in
tumour line HxVRC5 after various doses
of CY. At low doses (50 or 100 mg/kg) the
TFI recovers to the control level very
quickly, whereas at the higher doses (150
and 200 mg/kg) the TFI recovery times
are estimated to be 340 h and 600 h
150
|150
SO-
respectively. If the hypothesis that the
TFI recovery time correlates with growth
delay (rather than the level of the initial
depression) is correct, little or no growth
delay would be expected at low doses in
this tumour, whereas at higher doses (150
and 200 mg/kg) considerable growth delay
ought to be observed. Growth curves for
tumour HxVRC5 after treatment with
various doses of CY are presented in Fig.
4a. The growth curves for the other
tumour lines in Fig. 4 show that after
treatment, even at doses inducing con-
siderable growth inhibition, no volume
regressions were found. In most cases,
tumour growth continued at a reduced
rate, but appeared to recover to that of
untreated tumours (of the same line and
weight) by the time they had grown to 4
times the treatment volume (marked by
a horizontal arrow in Fig. 4).
Fig. 5 shows the relationship betweein
TFI recovery time and growth delay for
the corresponding dose of CY in tumour
30-
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FIG. 3. The pattern of TFI in tumour line
HxVRC5 after various (lose levels of CY:
A 50; 0 100; A 150; 200mg/kg.
TFI is expressed as a percentage of the
level measured in untreatedl tumours of
the same weight (mean±s.e.).
INTERVALS OF 6 DAYS
FiG. 4. Tumour growth curves following
various treatment: (a) HxVRC5 after CY;
(b) HxGC3 after CY; (c) HxELC2 after CY
and (d) HxELC2 after FU (note change of
scale). Figures above each curve refer to
the dose (mg/kg) of agent acdministered (Co
=Control). Treatment at the vertical
arrow, ancl growth delay assesse(l at t,he
horizontal arrow.
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ducing a similar TFI depression in two
individual tumour lines at a particular
TABLE II.-The TFI Recovery Time for 4
Tumour Lines after Treatment with Various
Agents, Compared to the Growth Delay.
There appears to be Considerable Agree-
rnent between the Two Measurements. r=
0-95 for the 36 Drug/Tumour Combina-
tions)
DOSE mg|kg
FIG. 5. In tumour line HxELC 2 the response
to CY as measured by growth delay (DO) or
TFI recovery time (*) was dose-dependent.
There appears to be a threshold dose
(16 mg/kg) below which there is nio
response to CY.
line HxELC 2. In general, the TFI re-
covery time and growth delay for the
same treatment are similar (Table II).
The data in Table II show the TFI
recovery time and the mean growth delay
for the 36 tumour: drug-dose combina-
tions examined to date, and indicate a
marked correlation between the two
measurements (r=0 96). It is of interest
that only I of the 4 human colonic
xenografts (HxELC2) showed a prolonged
depression of TFI after FU treatment.
The other tumour lines each showed an
increased uptake and utilization of this
"salvage" DNA precursor, and this ability
to utilize pre-formed TdR could account
for their relative insensitivity to FU
(Houghton, Houghton and Taylor, 1977b,
1977c).
The relationship between depression of TFI
and growth delay at one time after treatment
within a tumour line
It was shown above that it is not
possible to relate a given depression in
TFI 24 h after treatment to growth delay.
Similarly, with the depression in TFI 50 h
after various doses of CY in 3 xenograft
lines, it is clear that, although there may
be a relationship between the degree of
depression of TFI and its recovery time,
and growth delay within a tumour line,
this relationship is unique to each line
(Table Ill). Consequently, an agent in-
Tumour
line
HxHCl
HxGC3
HxVRC5
TFI
recovery Growth
Dose time delay
Passage Agent (mg/kg) (h) (h)
11 Act D 0-075 0 0
0-15 0 0
0-3 0 0
12 INLeCCNU 17-5 90 ND*
35 120 100
12 Cis-DDPt .3 0 0
6 45 ND
7 CY 50 0 0
100 50 0
200 80 0
7 FU 100 0 0
200 0 0
9 Act D 0-3 70 70
0-5 150 170
9 AMeCCNU 35 150 165
5 Cis-DDP' 3 0 ND
8 6 30 ND
5 CY o00 50 70
150 80 ND
200 110 170
300 190 250
5 FU 50 0 0
100 0 0
150 35 0
200 60 30
12 MeCCNU 35 550 560
6 CY 50 20 0
100 60 70
150 340 290
200 600 580
6 FU 50 0 0
100 0 0
150 0 ND
200 0 0
HxELC 2 5 MeCCNU 17-5 70 ND
35 150 ND
5 CY 50 100 130
l00 340 320
150 480 ND
200 700 670
5 FU 50 80 ND
100 300 450
150 500 ND
200 900 1140
5 Act D 0-075 30 0
0-15 40 70
0-3 80 140
* ND = Not determined.
t Cis-DDP = cis-platinum (II) diamine dichloride.
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TABLE III.--Per Cent Reduction in TFI
in 3 Xenograft Tumour Lines 50 h after
CY Treatment Compared to the Correspond-
ing TFI Recovery Time and Mean Growth
Delay Produced. It is Shown that for a
Given Level ofTFI Depression, the Recovery
Time and Growth Delay may Differ Con-
siderably between Tumour Lines
CY
Tuimour close
line (mg/kg)
HxGC3 :300
200
100
HxV'RC5 200
150
100
HxELC2 200
100
50
0% IMean
Reduction TFI
in TFI recovery
50 h after time
treatment (h)
82- 1 19(
7812 110
4-- 10 50
52=4
42 1
15-3
600
340
60
9791 700
52 + 5 340
30±4 100
Mean
growth
dtelay
(h)
250
70
58(
290
70
670
:320
130
time after treatment may delay the
growth of each tumour line quite differ-
ently. However, within a tumour line
there may be a relationship between
depression of TFI and growth delay that
is independent of the mechanism by which
the agent kills tumour cells (Houghton
and Taylor, ] 977a). Our previous ex-
periments uising rodent tumours suggested
that such a relationship may be estab-
lished at some time after the nadir of TFI
F-l RECOVER TO (h) GRCWTH DCLAY (h)
FI(G. 6. In tumour line HxELC2 results
from FU- an(l CY-treate(f animals have
been combined to establish a relationship
between TFI depression 100 h after
treatment, and other tumouir responses.
(a) TFI depression plotted against TFI
recoverytime fortumouirsreceivingthe same
treatment. (b) TFI depression plottedl
against mean growth (lelay for tuimours
receiving the same treatment. (Results are
mean ± s.e.).
depression. The relationship between
depression in TFI 4 days after treatment
and TFI recovery time or growth delav
in tumour line HxELC2 following FU
and CY treatment is shown in Fig. 6 (a) and
(b). The data showr that there is a sig-
nificant correlation between the depres-
sion of TFI at 4 days after treatment, the
TFI recovery time and the growth delay
in this tumour line. It has not been
possible in this study to determine
whether similar relationships exist for the
other 3 tumour lines studied, since these
lines were not sufficiently sensitive to the
drugs listed to enable meaningful relation-
ships to be established.
D)ISCUSSION
There appears to be general agreement
between mean growth delay and mean
TFI recovery time for the corresponding
treatment in this series of human colonic
xenografts. In each of the tumour-drug
combinations we have studied the post-
treatment growth rate has eventually
returned to that of the untreated control.
From this point onward, whether drug-
induced growth delay was assessed at 4,
6 or 8 times the treatment volume, the
result was the same (i.e. control and
treated tumour growth curves became
parallel). It would appear, therefore,
that the TFI recovery time corresponds
closely to the time at which the treated
tumour regains the same growth rate as
that measured in untreated tumours of
the same weight. If changes in TFI
were to parallel those in "clonogenic cells"
following treatment, it would be expected
that TFI would be depressed below
detectable levels for some time, followed
by a rapid recovery to the pretreatment
level, with a doubling time similar to
that of the repopulating cells. At times
soon after treatment, TFI is almost
certainly influenced by [3H]-TdR incor-
poration into doomed cells, and the shape
of the TFI recovery curve is probably
determined by the influix of cells into the
proliferative cycle and the efflux of drug-
'212
uI
I
I
I
ITdR INCORPORATION AND GROWTH IN TUMOUR XENOGRAFTS 213
killed cells which cease to proliferate after
a few days.
Several studies have attempted to
predict individual patient response by
examining the depression of radiolabelled
DNA precursor incorporation in biopsy
samples incubated with a selection of
cytotoxic agents in vitro. The data
presented here show clearly that, 24 h
after treatment, it is not possible to
predict tumour growth delay from changes
in TFI either within a group of human
colonic xenografts, or even within one
particular tumour line. Further, the agent
producing the greatest TFI 24-h depres-
sion within a tumour line may not induce
the greatest growth inhibition. Conse-
quently, it is not possible to select the
most effective agent by measurement of
[3H]TdR incorporation 24 h after treat-
ment. However, in our study, if there
was no depression in TFI at 24 h, no
growth delay was observed.
In the 4 tumour lines studied in this
work, there is a clear relationship between
growth delay and TFI recovery time
(n 36, r-0 96). In one tumour line
(HxELC2) we have been able to establish
a relationship between TFI depression 4
days after treatment and growth delay
(r-0 96) or TFI recovery time (r-086).
The time at which such a relationship is
established will probably vary with each
tumour line, but "calibration" ofa tumour
line in this manner may allow rapid
evaluation of single agents, or combina-
tions of agents.
It is not certain whether any of the
tumour-inhibitory effects presented in
this study would be regarded as positive
tumour responses in the clinic, for in each
case the tumours have continued to grow
after treatment, and the criterion of a
5000 reduction in the product of the
tumour diameters has not been satisfied.
However, that tumour growth inhibition
has been induced (Fig. 4a-d) is apparent
when the growth curves for treated
tumours are compared with those for
untreated tumours.
Our data show that the TFI recovery
time correlates with growth delay pro-
duced by the same treatment, and in the
laboratory, where tumouir lines may be
"calibrated", the assay may allow rapid
assessment of the value of drug combina-
tions and schedules. However, the data
show that changes in utilization of
[3H]TdR by tumours soon after the
administration of cytotoxic agents are a
poor indicator of tumour response in situ,
and such results obtained 1 day after
treatment must be regarded with caution.
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